WuXi Biologics Breaks Ground on Innovation Center in China

Global innovation center will integrate biologics discovery, development and clinical and commercial manufacturing.

Open-access biologics technology platform company WuXi Biologics announced that construction has begun in Fengxian, Shanghai, China on its new global innovation center. The 1.6 million–ft2 site will integrate biologics discovery, development and clinical and commercial manufacturing in a modular and flexible design and house more than 3000 scientists.

WuXi Biologics expects the new biologics center to further expand its capacities, enable it to develop and manufacture biologics more cost-effectively and ensure a robust supply chain network for its global partners, according to Chief Executive Officer Dr. Chris Chen.

Emilie Branch

Emilie is responsible for strategic content development based on scientific areas of specialty for Nice Insight research articles and for assisting client content development across a range of industry channels. Prior to joining Nice Insight, Emilie worked at a strategy-based consulting firm focused on consumer ethnographic research. She also has experience as a contributing editor, and has worked as a freelance writer for a host of news and trends-related publications